Figure 2 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors by Apostolia M. Tsimberidou (15294434)

Figure 2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study by Kentaro Sawada (21430568)

Data_sheet_1_Therapeutic effect of psilocybin in addiction: A systematic review.docx by Pim B. van der Meer (9606147)

Supplementary Figure S5 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibit... by James N. Ingle (8266752)

Table1_Research on prescribing cascades: a scoping review.docx by Zhe Chen (196097)

Population flowchart for analysis of therapeutic inertia. by Rohini Mathur (3122613)

Supplemental Figure S2 from A Bis-Indole–Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity by Keshav Karki (14944981)

Idea and process of this research. by Peng Zhang (2071)

Supplementary Video S1 from Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer by Frank Aboubakar Nana (8990171)

Figure S4 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies by Rodrigo A. Toledo (14996709)

Research process display. by Kui Xiao (10588658)

Subjects:

Supplementary Figures S1-S9 from Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death by Eric A. Lee (14918913)

Figure S6 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies by Rodrigo A. Toledo (14996709)

DataSheet1_Research on prescribing cascades: a scoping review.docx by Zhe Chen (196097)

Figure 4 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors by Constance A. Sobsey (19373550)

Figure 2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors by Constance A. Sobsey (19373550)

Figure S1 from The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer by Stephen Yiu Chuen Choi (14996076)

Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma by Marianna Carrabotta (8193039)

Image_1_Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma.tif by Emily C. Matchett (17037846)

“…Cells often undergo growth arrest, limiting their experimental utility; donor cells are extremely heterogeneous, resulting in content variability; and patients receiving allogeneic cells are at risk for graft-versus-host disease and/or cytokine release syndrome. Extracellular vesicles (EVs) have emerged as a new natural therapeutic tool. …”

Image_2_Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma.tif by Emily C. Matchett (17037846)

“…Cells often undergo growth arrest, limiting their experimental utility; donor cells are extremely heterogeneous, resulting in content variability; and patients receiving allogeneic cells are at risk for graft-versus-host disease and/or cytokine release syndrome. Extracellular vesicles (EVs) have emerged as a new natural therapeutic tool. …”